Regal holds 9.05% of Radiopharm Theranostics (RADX) stake disclosure

Rhea-AI Filing Summary

Radiopharm Theranostics Limited received a Schedule 13G from Australian investment entities affiliated with Regal Partners, disclosing beneficial ownership of 320,694,680 Ordinary Shares and equivalents as of 12/31/2025. This represents 9.05% of the outstanding class of Ordinary Shares and American Depositary Shares (ADSs).

The position includes 293,421,980 Ordinary Shares and 90,909 ADSs, with each ADS representing three hundred Ordinary Shares. Regal entities report no sole voting or dispositive power, but shared voting and shared dispositive power over 320,694,680 shares.

The Regal entities certify that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Radiopharm Theranostics.

Insights

Equity ownership and governance analyst

Regal discloses a 9.05% passive stake in Radiopharm Theranostics.

Affiliated Australian entities of Regal Partners report beneficial ownership of 320,694,680 Ordinary Shares and equivalents of Radiopharm Theranostics Limited, equal to 9.05% of the class. The position spans 293,421,980 Ordinary Shares and 90,909 ADSs, with each ADS representing three hundred Ordinary Shares, indicating a sizable institutional holding.

The filing states shared voting and dispositive power over all 320,694,680 shares and no sole authority, suggesting the stake is managed collectively across the Regal entities. The Schedule 13G certification specifies that the securities were acquired and are held in the ordinary course of business and not to change or influence control, placing this firmly in the category of a passive institutional investment rather than an activist position.

As this is a beneficial ownership disclosure rather than a transaction or strategic shift, its impact depends mainly on how investors view Regal as a long-term institutional holder. Future ownership reports or a form change (for example, to a different ownership schedule) would clarify whether this stake remains passive or evolves over time.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Radiopharm Theranostics Limited

(Name of Issuer)

Ordinary Shares, no par value and American Depositary Shares, each representing three hundred Ordinary Shares, no par value

(Title of Class of Securities)

75041J101

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 75041J101

1

Names of Reporting Persons

Regal Partners Holdings Pty Limited

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

AUSTRALIA

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 320,694,680.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 320,694,680.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

320,694,680.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.05 %

12

Type of Reporting Person (See Instructions)

FI

Comment for Type of Reporting Person: The number of shares beneficially owned includes: (i) 293,421,980 Ordinary Shares, no par value ("Ordinary Shares") and (ii) 90,909 American Depositary Shares, each representing three hundred Ordinary Shares.

SCHEDULE 13G

CUSIP No. 75041J101

1

Names of Reporting Persons

Regal Partners Funds Management Pty Limited

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

AUSTRALIA

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 320,694,680.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 320,694,680.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

320,694,680.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.05 %

12

Type of Reporting Person (See Instructions)

FI

Comment for Type of Reporting Person: The number of shares beneficially owned includes: (i) 293,421,980 Ordinary Shares, no par value ("Ordinary Shares") and (ii) 90,909 American Depositary Shares, each representing three hundred Ordinary Shares.

SCHEDULE 13G

CUSIP No. 75041J101

1

Names of Reporting Persons

Regal Partners Limited

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

AUSTRALIA

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 320,694,680.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 320,694,680.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

320,694,680.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.05 %

12

Type of Reporting Person (See Instructions)

FI

Comment for Type of Reporting Person: The number of shares beneficially owned includes: (i) 293,421,980 Ordinary Shares, no par value ("Ordinary Shares") and (ii) 90,909 American Depositary Shares, each representing three hundred Ordinary Shares.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Radiopharm Theranostics Limited
(b)	Address of issuer's principal executive offices: Level 3, 62 Lygon Street, Carlton Vic, Australia, 3053
Item 2.
(a)	Name of person filing: Regal Partners Holdings Pty Limited - CIK: 0001569369 Regal Partners Funds Management Pty Limited - CIK: 0002099534 Regal Partners Limited - CIK: 0001577774
(b)	Address or principal business office or, if none, residence: Level 46, Gateway, 1 Macquarie Place, Sydney NSW 2000
(c)	Citizenship: Australian
(d)	Title of class of securities: Ordinary Shares, no par value and American Depositary Shares, each representing three hundred Ordinary Shares, no par value
(e)	CUSIP No.: 75041J101
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
	FI
Item 4.	Ownership
(a)	Amount beneficially owned: 320,694,680
(b)	Percent of class: 9.05 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 320,694,680
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 320,694,680
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Regal Partners Holdings Pty Limited

Signature:	Ian Cameron
Name/Title:	Director
Date:	01/07/2026

Regal Partners Funds Management Pty Limited

Signature:	Ian Cameron
Name/Title:	Director
Date:	01/07/2026

Regal Partners Limited

Signature:	Ian Cameron
Name/Title:	Company Secretary
Date:	01/07/2026

FAQ

What stake in Radiopharm Theranostics (RADX) do the Regal entities report?

They report beneficial ownership of 320,694,680 shares, representing 9.05% of the outstanding class of Ordinary Shares and ADSs.

Which Regal entities filed the Schedule 13G for Radiopharm Theranostics (RADX)?

The filing is made by Regal Partners Holdings Pty Limited, Regal Partners Funds Management Pty Limited, and Regal Partners Limited, all organized in Australia.

How is the Regal position in Radiopharm Theranostics (RADX) split between Ordinary Shares and ADSs?

The reported holdings include 293,421,980 Ordinary Shares and 90,909 ADSs, with each ADS representing 300 Ordinary Shares.

Does Regal report control intentions over Radiopharm Theranostics (RADX)?

No. The certification states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

What voting and dispositive powers do the Regal entities have over their RADX holdings?

They report 0 shares with sole voting or sole dispositive power and 320,694,680 shares with shared voting and shared dispositive power.

What type of reporting person are the Regal entities in this 13G for RADX?

Each reporting person is classified as FI, and they certify that they qualify to file on Schedule 13G instead of a control-oriented schedule.